MK-1084 is an investigational medication being studied for the treatment of colorectal cancer, specifically in patients with KRAS G12C mutation. It belongs to a class of targeted therapy drugs.

Cetuximab is a medication that targets a protein called EGFR (epidermal growth factor receptor) on cancer cells. It is an antibody therapy that helps stop cancer cells from growing and spreading.

mFOLFOX6 is a combination chemotherapy regimen that includes several medications working together to kill cancer cells. It is commonly used to treat colorectal cancer.

Bevacizumab is a medication that works by blocking the formation of new blood vessels that feed tumors. It helps prevent cancer growth by cutting off the tumor’s blood supply.

Colorectal Cancer – A disease that begins in either the colon or rectum, which are parts of the large intestine. It typically starts as small growths called polyps that form on the inner lining of the colon or rectum. Over time, some of these polyps can develop into cancer. In this specific case, the cancer has a KRAS G12C mutation, which means there is a specific change in the DNA of cancer cells. The cancer is considered locally advanced when it has grown through the wall of the colon or rectum and may have spread to nearby structures. When described as metastatic, it means the cancer has spread from its original location to other parts of the body.